Areteia Therapeutics
ClosedCommitted to putting asthma patients in better control
Chapel Hill, United States · Founded 2022 · $425.0M raised
- Headquarters
- Chapel Hill, North Carolina
- Employees
- 11–50
- Founded
- 2022
- Business Model
- B2B
- Website
- areteiatx.com
- Total Funding
- $425.0M
- Last Round
- $75.0M Series AFeb 2024
- Rounds
- 2
About
Areteia Therapeutics was a clinical-stage biotechnology company developing dexpramipexole, an oral eosinophil-maturation inhibitor, to treat eosinophilic asthma and put patients back in control of their disease. Focused on novel inflammation and immunology therapies, it raised $425M in funding led by ARCH Venture Partners and GV. The company wound down operations in late 2025 amid Phase 3 drug trials.
Summary
Areteia Therapeutics is a Biotech company based in Chapel Hill, United States, founded in 2022. It has raised $425.0M in total across 2 rounds, most recently a $75.0M Series A round in Feb 2024.
Tech & App Stack
7 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Feb 2024
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Similar Companies
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...
Develops Gene Writing technology and non-viral delivery to create in vivo genetic medicines for m...
San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.